By SPC News Staff
The FDA approved the first interchangeable biosimilar product insulin glargine-yfgn (Semglee, Viatris/Biocon).
As an interchangeable biosimilar product, insulin glargine-yfgn may be substituted for the reference product Lantus (Sanofi) at the pharmacy without the intervention of the prescribing health care provider, subject to state pharmacy laws.